A key element of any immune response is the strict regulation of immune activation to prevent responses to self-Ags, promote responses to foreign Ags, and limit collateral damage. Naturally occurring CD4 ϩ CD25 ϩ FoxP3 ϩ regulatory T cells maintain immunological self tolerance (1) and play a key role in the structural organization of an immune response (2) , and myriad attempts have been made to harness their suppressive capacities. A vast number of murine studies have shown that either the in vivo generation/expansion or adoptive transfer of regulatory T cells can prevent various T cell-mediated diseases, i.e., autoimmunity (3), graft-vs-hostdisease (4), and allograft rejection (5). Two major conclusions can be drawn from these studies. First, regulatory T cells are relatively weak, and large numbers are needed, often in a 1:1 ratio with effector T cells to prevent disease induction or progression. Under physiological conditions, this weakness might be required to allow T cell effector function to be generated against foreign Ags. Second, it has been shown in murine models of graft-vs-host disease and experimental autoimmune encephalomyelitis (3) that Ag-specific CD4 ϩ CD25 ϩ FoxP3 ϩ regulatory T cells were always more protective than Ag-nonspecific CD4 ϩ CD25 ϩ FoxP3 ϩ regulatory T cells (4). Thus, the enrichment of Ag-specific T cells, which has been shown to be possible in one human study (6), and expanding them to effective numbers are key factors for the successful use of regulatory T cells in any clinical setting.
Although the above results are promising, there are only a few studies that have looked at the ability of regulatory T cells to reverse an already established inflammatory process (7, 8) . A likely explanation for this limitation is the fact that regulatory T cells have to act within an already established inflammatory milieu, and certain proinflammatory cytokines either induce resistance to T cell-mediated suppression (9), or microbial products alter the suppressive capacity of regulatory T cells (10). This is also a problem for tolerance induction protocols, which fail when the recipient is concomitantly exposed to inflammatory stimuli (11). Therefore, it has been proposed that the control of the inflammatory cytokine milieu is an essential precondition for regulatory T cells to be effective. As the first line of defense, the innate immune system informs and shapes the ensuing adaptive immune response through the sensing of microbial products via pattern recognition receptors and initiation of an inflammatory cascade. Recent in vitro and in vivo evidence has suggested that T cells are able to inhibit this early innate immune response (12) . It is therefore feasible that the early blockade of overt inflammation could in turn favor a situation where regulatory T cells would be able to suppress an adaptive immune response.
To address this latter possibility, we took advantage of the strain-specific expression of minor lymphocyte-stimulating (Mls) 5 genes, which encode endogenous superantigens. These superantigens are part of the mouse mammary tumor virus (MMTV) genomes that have become integrated at various sites into the mouse genome (13) . The Mls genes were named for their ability to stimulate strong proliferative responses of CD4 ϩ T cells in mixed lymphocyte cultures between strains identical at the MHC locus. In Mls-Ag-bearing strains, T cells expressing certain V␤ families that bind to the Mls protein die by apoptosis during intrathymic maturation. DBA/2 (H2 d ) mice, which were used in the current study, lack V␤6
ϩ , V␤7 ϩ , V␤8.1 ϩ , and V␤9 ϩ T cells due to the expression of Mls-1 a Ag encoded by MMTV7 (14) . This intrathymic deletion requires the thymic copresentation of the Mls-1 a Ag with MHC class II molecules (15) . Interestingly, DBA/2 (H2 d ) Mls-1 apositive splenocytes can also be used to induce tolerance in BALB/c Mls-1 a -negative mature T cells. Rammensee et al. (16) showed that the injection of DBA/2 splenocytes into MHC-identical BALB/c mice reversed the normal vigorous proliferation of BALB/c T cells when mixed with DBA/2 APC. The lack of T cell response was not explained simply by deletion, because V␤6 ϩ
CD4
ϩ T cells were still detectable in significant numbers after the injection.
We report here that the injection DBA/2 splenocytes into BALB/c mice leads to an increase of Mls-1 a -specific V␤6
Upon in vivo sensitization with LPS-matured DBA/2 dendritic cells (DC), these animals failed to recruit NK cells and granulocytes to the draining lymph node (LN), and adoptively transferred naive DO11.10 T cells were actively suppressed in their response to OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] . These data suggest that preactivation of regulatory T cells may greatly enhance their suppressive potential and could increase their therapeutic potential.
Materials and Methods

Mice, culture media, reagents, and Abs
Female BALB/c (Mls-1 b , H2 d ), DBA/2 (Mls-1 a , H2 d ), of 6 -8 wk old were purchased from Charles River Laboratories U.K. Rag replete DO11.10 were bred and maintained in the Biological Services Unit (NHH) of King's College London. Mice were kept under sterile conditions. Mouse handling and experimental procedures were conducted in accordance with national and institutional guidelines for animal care and use. RPMI 1640 medium supplemented with L-glutamine (Life Technologies), penicillin/streptomycin (Life Technologies), and 10% (v/v) FCS (Harlan Sera-Lab) was used for all in vitro assays. For cell purification and washing steps, RPMI 1640 medium supplemented with 2% FCS was used. All Abs used were purchased from BD Pharmingen, except for anti-FoxP3-APC (clone FJK-16s), which was obtained from eBioscience.
Induction of tolerance
BALB/c mice were injected in the tail vein with 15 ϫ 10 6 ACK-treated DBA/2 spleen cells suspended in 0.2 ml of PBS. Control animals received the same amount of BALB/c spleen cells. Animals then rested for 10 days before performing additional experiments.
Preparation of mouse CD4
ϩ CD25 Ϫ and CD4 ϩ CD25 ϩ T cells
Spleen and LN were harvested from BALB/c mice. CD4 ϩ T cells were prepared by using the Dynal CD4 Negative Isolation Kit (Dynal Biotech). The purified CD4 ϩ T cells were then incubated with biotinylated anti-CD25 Ab (clone 7D4; BD Pharmingen) for 20 min in ice and followed by incubation with streptavidin microbeads (Miltenyi Biotec) for 15 min at 10°C. CD4 ϩ CD25 Ϫ T cells were separated from CD4 ϩ CD25 ϩ T cells by passing through a MACS column. The unbound fraction contained the CD4 ϩ CD25 Ϫ T cells. CD4 ϩ CD25 ϩ T cells were eluted from the column. The purity of the cells was checked by flow cytometry. On the basis of the FACS results, a total number of 10 ϫ 10 6 CD4 ϩ CD25 Ϫ or CD4 ϩ CD25 ϩ were injected into DBA/2 mice in 200 l of PBS.
Generation of DC
DC were generated from bone marrow. Briefly, bone marrow cells (5 ϫ 10 5 /ml) were treated with a mixture of anti-CD8, anti-CD4, anti-B220, and anti-MHC class II supernatants (YTS169, YTS191, RA34.5, and M5/114) for 30 min. After Ab treatment, the cells were washed and incubated with goat anti-rat IgG dynal beads (Dynal Biotech) for 30 min. Unbound cells, which are enriched with precursor cells, were cultured with 10% FCS RPMI 1640 containing 5% (v/v) supernatant from a GM-CSF-secreting transfected cell line. On days 2 and 4, nonadherent cells were removed. Fresh medium with GM-CSF was added to the adherent fraction for continuing culture. DC maturation was induced by incubating the cells overnight with 0.5 g/ml LPS (055:B5; SigmaAldrich) and then used on day 8.
Immunization and Ab treatment
Spleen and LN were harvested from DO11.10 mice. CD4 ϩ T cells were prepared by using the Dynal CD4 Negative Isolation Kit (Dynal Biotech). For in vivo proliferation, cells were first labeled with 1 M CFSE for 5 min at 37°C, followed by two washes with ice-cold RPMI 1640 supplemented with 10% FCS and resuspended in PBS for i.v. injection. We injected 3 ϫ 10 6 CD4 ϩ KJ1-26 ϩ into syngeneic BALB/c mice on day 10. The following day mice received 0.5 ϫ 10 6 OVA 323-339 peptide (Peptides International)-pulsed LPS-matured DC s.c. into the hind leg. Animals were culled 4 days later, and the draining LN was harvested. For blocking of CTLA-4 signaling, 300 g of clone UC10-4F10-11 or hamster IgG1 isotype control (BioXCell) was injected on days 10 -12 around the time of DC injection (day 11).
MSD multiplex assay
For cytokine analysis, draining LN cells were meshed through a cell strainer and concentrated at 2 ϫ 10 6 /ml in supplemented RPMI 1640. Unseparated LN cells (2 ϫ 10 5 ) were then seeded into 96-well round-bottom plates and incubated for 48 h. Supernatants were taken from these cultures and frozen at Ϫ20°C. 7-Plex proinflammatory cytokine assays were performed on MSD MULTI-SPOT plates in accordance with the manufacturer's guidelines (Meso Scale Discovery). In short, 25 l of supernatant or standard solution was added to Ab-coated plates; this was followed by a mix of labeled detection Abs. After a washing step and the addition of the reading buffer, the plate was immediately read on a SECTOR Imager. All assays were performed in duplicates.
Flow cytometric analysis
All flow cytometry acquisition was conducted on a BD Biosciences FACSCalibur running CellQuest software (BD Biosciences). For analysis, we used FlowJo software (Tree Star). For surface staining, 5 ϫ 10 5 cells were incubated with saturating concentrations of appropriate Abs for 30 min at 4°C in the dark and then washed twice in cold FACS buffer (PBS with 1% (v/v) FCS and 0.01% (w/v) sodium azide) before analysis. FoxP3 staining was performed according to the manufacturer's guidelines.
Statistical analysis
All statistical tests were performed using GraphPad Prism version 4.0b for Macintosh (www.graphpad.com; GraphPad Software). The applied statistical tests are noted in the figure legend or Results, and a value of p Ͻ 0.05 was deemed significant. a -specific T cells mice, followed by a contraction phase (17) . This led to a reversal of the normal vigorous proliferation of BALB/c T cells when mixed in vitro with DBA/2 APC (16) or when rechallenged in vivo (17) . To quantitate these effects, 15 ϫ 10 6 DBA/2 splenocytes or 15 ϫ 10 6 BALB/c splenocytes as control were injected into naive BALB/c mice. Ten days later, we stained CD4 ϩ T cells for a variety of V␤ chains and for the expression of CD25 and FoxP3 molecules. The pretreatment with Mls-1 a splenocytes lead to a significant decrease in the percentage of V␤6 ϩ CD4 ϩ T cells from 10.6 Ϯ 1.5% to 7.1 Ϯ 1.2% (n ϭ 12) (Fig. 1, A and B) , whereas the percentage of Mls-1 a -nonreactive V␤10 ϩ CD4 ϩ T cells did not change during the same period. Since the absolute number of recovered T cells showed no significant differences between the two groups at day 10 (data not shown), differences in percentage among the V␤ families reflect differences in absolute numbers of T cells (Fig. 1B) .
Results
Injection
The overall percentage of CD4 ϩ FoxP3 ϩ T cells was not different between the two groups (Fig. 1C) 
CD4
ϩ T cells in naive DBA/2 mice (Fig. 1F , top row). Similar to other animal models in which transgenic T cells encounter their specific peptide during thymic development, a large proportion of the peripheral V␤6 ϩ CD4 ϩ T cells in the DBA/2 mice were FoxP3 positive (58.4 Ϯ 4.6%; Fig. 1F , second row) (20) . The existence of V␤6 ϩ CD4 ϩ T cells in DBA/2 mice was also supported by a study from Yosheda et al. (21) , in which V␤6 ϩ T cells in DBA/2 mice were detected using a PCR-based microplate hybridization assay.
The injection of CD4 ϩ CD25 Ϫ T cells derived from BALB/c into DBA/2 mice led to a massive expansion (ϳ40 times) of the V␤6 ϩ CD4 ϩ BALB/c T cells (Fig. 1F , top row) whereas V␤10 ϩ CD4 ϩ T cells remained stable ( ϩ and V␤10 ϩ cells among the total CD4 ϩ was measured after injecting either BALB/c (Ⅺ) or DBA/2 (f) splenocytes. Data are mean Ϯ SEM of three independent experiments (n ϭ 12), and statistical analysis was performed using a two-way ANOVA; ‫,ء‬ p Ͻ 0.001. C, Experiment as in A, four-color FACS staining was performed for CD4, V␤s, CD25 and FoxP3, and CD4-and V␤6/10-gated populations were analyzed for the distribution of CD25 and FoxP3. A representative experiment out of three is shown. D, Experiment as in A, the percentage of FoxP3 ϩ cells among total CD4 ϩ , CD4 ϩ V␤6 ϩ , and CD4 ϩ V␤10 ϩ was measured after injecting either BALB/c (Ⅺ) or DBA/2 (f) splenocytes. Data are mean Ϯ SEM of three independent experiments (n ϭ 12), and statistical analysis was performed using a two-way ANOVA; ‫,ء‬ p Ͻ 0.001. E, Experiment as in A, T cells were negatively selected from inguinal, popliteal, axillary, and mesenteric LN and spleens, and the total number of CD4 ϩ V␤6 ϩ FoxP3 ϩ and CD4 ϩ V␤10 ϩ FoxP3 ϩ was calculated according to FACS staining after injecting either BALB/c (Ⅺ) or DBA/2 (f) splenocytes. Data are mean Ϯ SEM of three independent experiments (n ϭ 12), and statistical analysis was performed using a two-way ANOVA; ‫,ء‬ p Ͻ 0.001. F, A total of 10 ϫ 10 6 purified CD4 ϩ CD25 Ϫ (purity Ͼ95%) or CD4 ϩ CD25 ϩ (purity Ͼ90%) BALB/c T cells were injected into DBA/2 mice (n ϭ 3/group). Mice were culled 7 days later, and splenocytes were stained for V␤6, V␤10, CD4, CD25, and FoxP3. Experiments were performed twice with similar results; representative results are shown.
naturally occurring regulatory T cells (19) . Since the absolute numbers of V␤6 ϩ CD4 ϩ CD25 Ϫ and V␤6 ϩ CD4 ϩ CD25 ϩ of injected T cells (10% of total CD4 ϩ T cells) were similar, this experiment also suggest that superantigen-reactive CD25 ϩ and CD25 Ϫ CD4 ϩ T cells behave differently when encountering their Ag in vivo similarly to MHC peptide-specific T cells (20) .
Activated regulatory T cells inhibit early activation and accumulation of cells of the innate immune system
The observed increase in V␤6 ϩ T cells with a regulatory phenotype did not necessarily mean that effective regulation was induced. Indeed, T cell hyporesponsiveness has not been reproducibly demonstrated in vitro in the Mls system (17) . Since in vitro studies fail to mimic the precise anatomy of immune responses, we chose to study the regulatory potential of surviving Mls-1 a -reactive T cells in vivo.
First, we tested whether Mls-1 a -specific hyporesponsiveness in BALB/c animals in vivo was induced by pretreatment with DBA/2 splenocytes. BALB/c mice, which had received DBA/2 splenocytes (treatment group) or BALB/c splenocytes (control group) 10 days earlier, were injected with LPS-matured DBA/2 DC s.c., and the kinetics of the ongoing immune response in the draining LNs was monitored. It has been reported that LPS-matured DC traffic to the draining LN, and this event led to a massive increase in LN cellularity, which was sustained for several days ( Fig. 2A ). The pretreatment with DBA/2 splenocytes significantly inhibited the increase in LN size and in cell numbers. Ten days after the DC injection, the LN size in the treatment group was similar to a resting LN, whereas the draining LN in the control animals were still massively enlarged ( Fig. 2A) .
Recently, we have shown that T cells play a pivotal role in the induction and/or maintenance of reactive LN (22) . On the basis of this, we reasoned that the pretreatment with DBA/2 splenocytes influences the early activation of T cells in the draining LN and hence could suppress the increase in size and cellularity. To investigate this, the percentage of CD25 ϩ and FoxP3 ϩ T cells was analyzed at day 2, at a time point where no significant differences in LN size and cell number between the two animal groups were observed ( Fig. 2A) . The expression of FoxP3 (2, 23) and the combination of CD25 expression and lack of FoxP3 were used to identify regulatory T cells and recently activated effector T cells, respectively. CD4 ϩ T cells from the LN of animals from the control group showed a marked increase in the percentage of T cells expressing both markers (Fig. 2B) . In contrast, CD4 ϩ T cells from DBA/2-pretreated animals showed only a small increase of the CD4 ϩ CD25 low FoxP3 Ϫ population (Fig. 2B) We have previously shown that migration of LPS-matured DC into the draining LN induced a strong Th1 response, which depended on migrating NK cells as an early source of IFN-␥ (24). We therefore investigated the early influx of NK cells and found that it was inhibited in a DBA/2-specific manner (Fig. 2C, bottom  row) , because LPS-matured BALB/c DC were still able to induce NK cell migration in DBA/2-pretreated animals (Fig. 2C, bottom  row) . This excluded the possibility of a general migratory defect in animals pretreated with DBA/2 splenocytes. In addition, no differences were observed in the capacity of BALB/c and DBA/2 DC to induce the early migration of NK cells when the animals were pretreated with BALB/c splenocytes (Fig. 2C, top row) . Granulocytes (Gr-1 high CD11c Ϫ PDCA-1 Ϫ (25-27)) were also induced to migrate following LPS-DC injections in animals pretreated with BALB/c splenocytes. Granulocytes have a major role in innate immunity, but recent evidence indicates that they also contribute to adaptive immunity (28) . They attract immature DC via the release of MIP-1␣, MIP-1␤, and ␣-defensins, they interact with DC (29), they induce DC maturation partially through the release of TNF-␣, and they instruct DC to induce Th1 polarization (30) . Similar to the NK cells, granulocytes were absent in animals pretreated with DBA/2 splenocytes and sensitized with LPS-matured DBA/2 DC (Fig. 2D) .
Taken together, these data provide evidence that the normal inflammatory response is severely reduced in a DBA/2-specific manner and that migration into the LN of two important cell populations of the innate immune system, which provide help for the adaptive immune response, was markedly inhibited.
To exclude the possibility that the observed suppression was the simple result of an increase in the absolute number of V␤6 ϩ CD4 ϩ CD25 ϩ T cells (Fig. 2E) , we selected naive CD4 
CD25
ϩ T cells before the sensitization or those who did not (1.95 Ϯ 0.16% vs 2.08 Ϯ 0.10%, p Ͼ 0.05, paired t test). On the basis of this experiment, we can conclude that a mere numeric increase of regulatory T cells is not sufficient to induce suppression and that the preactivation of resident T cells is essential for the observed inhibition of immune und inflammatory responses.
Superantigen-dependent suppression of OVA-specific naive T cells
To further investigate whether pretreatment with Mls-1 a cells could also influence the adaptive response, naive DO11.10 T cells were adoptively transferred into BALB/c animals. The TCR expressed by DO11.10 T cells consists of V␣13 and a V␤8.2 chain and is therefore unresponsive to Mls-1 a Ag (Ref. 31 and data not shown). In addition, DBA/2 DC (H2 d ) and BALB/c DC (H2 d ) are equally effective in stimulating DO11.10 T cells when pulsed with OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] (Fig. 3) . Naive DO11.10 T cells were transferred into BALB/c animals 10 days after they were pretreated with either BALB/c or DBA/2 splenocytes. The following day LPS-matured OVA-pulsed DC of either BALB/c or DBA/2 origin were injected s.c., and 48 h later, the expression of CD25 and L-selectin (CD62L) molecules on DO11.10 T cells was analyzed. At that time point, the number of cells per LN ( Fig. 2A) and the percentage of adoptively transferred DO11.10 cells was similar in all sensitized groups (data not shown). Pretreatment with DBA/2 splenocytes 10 days before sensitization with DBA/2 DC significantly suppressed Ag-specific activation, as shown by a reduced up-regulation of CD25 compared with animals pretreated with BALB/c splenocytes ( Fig. 3A; 45.7 Ϯ 4.3% vs 76.2 Ϯ 8.6%, p Ͻ 0.05, paired t test). It also led to impaired down-regulation of CD62L when comparing the same groups ( Fig. 3B ; 68.2 Ϯ 3.9% vs 81.2 Ϯ 4.5%, p Ͻ 0.05, paired t test). To address the possibility that the pretreatment with DBA/2 splenocytes induced a state of general impairment of CD4 ϩ T cell responses, DBA/2-pretreated mice were injected with LPS-matured OVA-pulsed BALB/c DC. The extent of up-regulation of CD25 and down-regulation of CD62L by DO11.10 T cells was the same as that seen in control animals.
This result clearly shows that the pretreatment with DBA/2 splenocytes per se is not enough to inhibit the ability of the mice to mount a sufficient CD4 ϩ T cell response.
To investigate whether this early impairment of T cell activation resulted in a failure to proliferate at a later stage, we injected CFSE-labeled DO11.10 T cells in Mls-1 a -pretreated animals. The Ten days later, mice were sensitized s.c. with 2 ϫ 10 6 LPS-matured DBA/2 DC. On days 0, 2, 4, 6, and 10, mice were culled, and draining LN cells were counted. Data points are plotted as mean Ϯ SEM. To compare absolute cell numbers, a paired t test was performed for every single time point; ‫,ء‬ p Ͻ 0.01. B, Experiment as in A, on day 2, four-color FACS staining was performed to evaluate the pattern of CD25 and FoxP3 in whole CD4 and specifically CD4 ϩ V␤6 ϩ T cells. C, A total of 15 ϫ 10 6 unseparated splenocytes (BALB/c or DBA/2) were injected i.v. into BALB/c mice (n ϭ 9/group). Ten days later, each group was divided into three subgroups, which 1) remained unsensitized (n ϭ 3), 2) were sensitized s.c. with 2 ϫ 10 6 LPS-matured BALB/c DC (n ϭ 3), or 3) were sensitized s.c. with 2 ϫ 10 6 LPS-matured DBA/2 DC (n ϭ 3). On day 2, the mice were culled, and draining LN cells were stained for DX5 and CD3 to identify NK cells. D, Experiment as in C, draining LN cells were stained for Gr-1 and PDCA-1 to identify granulocytes, which also had a distinct FSC high scatter profile (data not shown). E, CD4 ϩ CD25 ϩ T cells (5 ϫ 10 6 ) were selected from BALB/c mice and injected into BALB/c mice. One day later, these animals and a control group of unmanipulated BALB/c mice (n ϭ 3/group) were sensitized with 2 ϫ 10 6 LPS-matured DBA/2 DC. Two days later, the animals were culled, and the recruitment of NK cells to the draining LN was compared between the two groups. Experiments were performed twice for the kinetics and three times for FACS analysis on day 2 with similar results; representative results are shown.
following day OVA-pulsed mature DBA/2 DC were injected s.c., and CFSE division was analyzed after 4 more days. In animals pretreated with DBA/2 splenocytes and sensitized with DBA/2 DC, a reduced accumulation and activation status of DO.11.10 T cells was observed (Fig. 4A and Table I ). Furthermore, by calculating the number of DO11.10 cells in division, animals that were pretreated with BALB/c splenocytes had 20 times more DO11.10 T cells in division in the draining LN than animals pretreated with DBA/2 ( Table I) .
To investigate the functional consequences of the inhibition in the activation and proliferation of the transferred DO11.10 T cells, the production of inflammatory cytokines (IL-12p70, IFN-␥, TNF-␣, and IL-6) in the draining LN was measured (Fig. 4B) . To best reflect the in vivo situation, homogenized draining LN were cultured for 48 h, and supernatants were harvested (28) . The profile of proinflammatory cytokines mirrored the proliferation and activation data in the draining LN. TNF-␣ and IL-6 have been identified as two proinflammatory cytokines, which are able to abrogate regulatory T cell function (12) , and the blockade of TNF-␣ can "reauthorize" regulatory T cells to suppress (32) . The presence of these cytokines in the control group may be necessary to inhibit the function of V␤6 ϩ CD4 ϩ FoxP3 ϩ T cells when these cells encounter matured DBA/2 DC. The absence of these cytokines in the DBA/2 splenocyte-pretreated animals could allow suppression to take place. The absence of any detectable keratinocytederived chemokine (KC or CXCL1) and MIP-2 (CXCL2), which are the major chemoattractants for the recruitment of granulocytes, matched very well with the absence of granulocytes. Surprisingly, IL-10, which has been involved in regulation following treatment with various superantigens (33), was not detectable in the DBA/ 2-pretreated group but was present in the supernatants of control animals.
Taken together, these data provide evidence that the pretreatment of BALB/c mice with DBA/2 splenocytes activates regulatory T cells, which inhibit the activation and proliferation of Agspecific T cells in a DBA/2-dependent manner. 
KJ1-26
ϩ cells were adoptively transferred on day 10 after splenocyte treatment into BALB/c mice (n ϭ 4/group) who were 1) naive, 2) pretreated with 15 ϫ 10 6 BALB/c splenocytes, or 3) pretreated with 15 ϫ 10 6 DBA/2 splenocytes. On the following day (day 11), mice were challenged s.c. with 1 ϫ 10 6 LPS-matured OVA 323-339 -pulsed DC or left unsensitized. Four days later, mice were culled, and the LN were removed. For histogram analysis, 4 ϫ 10 5 life events (according to scatter profile) were collected, and the shown data are gated on CD4 ϩ KJ1-26 ϩ T cells. In addition, the activation status of the transferred cells was determined by CD44 staining of gated CD4 ϩ KJ1-26 ϩ T cells. B, For cytokine analysis, 2 ϫ 10 5 unseparated LN cells were cultured for 48 h without further stimulation in 96-well plates. Supernatants were taken, and cytokines and their standards measured in duplicates with a 7-plex-MULTISPOT assay from MSD. Note the different yaxis for the different cytokines. To compare cytokine production between the three groups, a one-way ANOVA test was performed; ‫,ء‬ p Ͻ 0.001. Experiments were performed twice with similar results; representative results are shown.
whether CTLA-4 played any role in the regulatory function of FoxP3 ϩ Mls-1 a -reactive T cells, animals were injected with three doses of anti-CTLA-4 Abs around the time of sensitization (38) . Four days later, the percentage of recovered DO11.10 T cells in the draining LN was determined. In animals that have been pretreated with BALB/c splenocytes, the addition of anti-CTLA-4 Ab did not lead to a significant change in the percentage of recovered DO11.10 T cells compared with addition of isotype control Ab (Fig. 5A, top row) . In contrast, injection of anti-CTLA-4 Abs to animals, which were pretreated with DBA/2 splenocytes, led to a significant increase in the percentage of recovered DO11.10 cells compared with the animals treated with the isotype control Ab (Fig. 5A , bottom row, 2.1 Ϯ 0.2% vs 1.2 Ϯ 0.2%, p Ͻ 0.05, paired t test). This increase was accompanied by an up-regulation of CD44 expression on all the DO11.10 T cells. However, anti-CTLA-4 did not reverse the suppression of cytokines (data not shown) as measured in Fig.  4B . Altogether these data indicate that anti-CTLA-4 Ab partially reversed the local suppression of the DO11.10 T cells in the draining LN. We performed similar experiments using neutralizing Abs specific for TGF-␤, which showed no effect in agreement with previous reports (39).
Discussion
We have provided evidence in this study that superantigen-expressing splenocytes induce a state of dominant tolerance. This state is characterized by the partial deletion of Mls-1 a -specific CD4 ϩ FoxP3 Ϫ T cells and an increase in Mls-1 a -specific CD4 ϩ FoxP3 ϩ T cells. Furthermore, the preactivation of superantigenspecific regulatory T cells inhibited NK cell and granulocyte entry to the local LN and inhibited the activation and differentiation of Ag-specific T cells with a different specificity. The linked suppression of OVA-specific T cells depended on the copresentation of the superantigen and the OVA peptide at the time of sensitization.
There are only a few reports investigating the influence of regulatory T cells on the innate immune system. Recent reports have hinted at a close relationship between the innate and the adaptive immune system whereby the former has an essential impact on the type and magnitude of the final response. It is therefore conceivable that regulatory T cells have an influence on the innate immune system to suppress an ongoing immune response in its early stages. Kim et al. (12) reported that CD4 ϩ T cells were able to suppress an unleashed innate immune response in vivo within the first 6 h of TLR stimulation, arguing against the notion that the innate and the adaptive immune response are sequential events. We have shown that granulocytes and NK cells are inhibited in their early migration to the inflamed LN. The preactivation of the endogenous regulatory T cells (as discussed below) was vital for this inhibition to take place, because nontolerized BALB/c mice showed no difference in the pattern of migration of innate immune cells when sensitized with either BALB/c or DBA/2 DC whereas animals Fig. 4A , we calculated the number of dividing CD4 ϩ
KJ1-26
ϩ T cells (mean Ϯ SEM). For statistical comparison, we performed paired t test between BALB/c splenocyte-pretreated animals and DBA/2-pretreated animals ‫,ءء(‬ p Ͻ 0.001) and between DBA/2-pretreated animals and controls ‫,ء(‬ p Ͻ 0.01); pooled data of two independent experiments are shown. treated with DBA/2 splenocytes did. The fact that the suppression only occurred when the animals were sensitized with DBA/2 DC but not BALB/c DC clearly shows its Ag dependency and thus the influence of the adaptive immune system on the innate. Being among the first cells which are recruited to sites of infection and inflammation granulocytes are able to serve different purposes in innate and adaptive immunity. Granulocytes release various chemokines to attract other immune cells and proinflammatory cytokines, including IL-12 and TNF-␣, which via activation and maturation of DC promote Th1 polarization (29, 30, 40, 41) . In addition, they are even able to shuttle Ag from the periphery to the draining LN (42) and cross-prime naive T cells (43) . This is supported by NK cells, which as an early source of IFN-␥ have been identified as a key component for the induction of a Th1 response in certain models (24, 44) . Examining cytokine-activated islet isolates Chen et al. (45) could show that CD4 ϩ CD25 ϩ regulatory T cells were able to significantly suppress the translational and transcriptional up-regulation of chemokines in islet cells and consequently the migration of T cells in Transwell experiments. This is in line not only with the altered migration of NK cells and granulocytes but also with the overall cytokine production and kinetics of the inflammatory response ( Figs. 2 and 3) .
Another interesting dimension that emerged from this study was that our findings maybe explain how retroviruses coexist with their host and escape elimination. Active regulation by the host immune system may be an important factor in the retroviruses survival strategy as has been shown for other pathogens (46 -48) . This is corroborated by a recent publication, which looked at the superantigen-specific CD4 ϩ T cell response after infecting BALB/c mice with the milk-borne betaretrovirus MMTV7, which expresses Mls-1 a . It was shown that the early infection of BALB/c mice is governed by the preferential expansion of superantigen-specific CD4 ϩ CD25 ϩ FoxP3 ϩ T cells leading to ϳ25% V␤6 ϩ CD4 ϩ T cells expressing FoxP3 2 wk after infection. These cells had superior Mls-1 a -specific suppressive capacity over CD4 ϩ CD25 ϩ T cells from uninfected mice (49) . We have confirmed and extended those findings by demonstrating for the first time in vivo that the superantigenactivated regulatory T cells are able to suppress essential parts of the innate and adaptive immune system, which ultimately leads to the suppressed activation, proliferation, and effector function of T cells, which are not responsive to the superantigen. The presented findings address three important issues. First, they help to explain the inability to quickly clear superantigen-encoding pathogens by inhibiting a sufficient T cell response against other pathogen-derived Ags. Second, the local suppression of T cell-dependent immune responses could make animals more prone to acquire superinfections by other microorganisms. Third, the impaired immune response promotes long-lasting coexistence, which might in turn facilitate the insertion of so many retroviral sequences into the mouse genome (13) . This on the other hand does not contradict the possible link between different autoimmune diseases and certain superantigens (50 -52) .
Our model clearly shows that two events are imperative for dominant regulation to take place. First, the endogenous regulatory T cells had to be preactivated to give them an advantage over the adoptively transferred naive DO11.10 T cells. Animals that were pretreated with BALB/c splenocytes had considerable numbers of V␤6 ϩ CD4 ϩ FoxP3 ϩ T cells (Fig. 1, C-E) ; however, these cells were unable to control the activation and proliferation of DO11.10 T cells (Figs. 3 and 4) . Hence, the preactivation of endogenous DBA/2-responsive T cells with DBA/2 splenocytes was essential to inhibit the response of the DO11.10 T cells when OVA was presented on mature DBA/2 DC (Figs. 3 and 4) . Second, the adoptively transferred DO11.10 cells could only be suppressed when the superantigen and the OVA peptide were presented simultaneously in the same LN upon challenge. Therefore, a T cell with cross-reactivity for self, which is activated by superantigen-induced polyclonal activation of T cells, could escape regulation, if there are insufficient-activated regulatory T cells. Another level of complexity is added by the fact that humans have a much higher percentage of memory T cells than mice. There are conflicting data on whether memory T cells can be suppressed (53, 54) or rendered tolerant (55) , making it possible that even when regulatory T cells have been preactivated by a previous encounter, autoimmunity or relapses of autoimmune diseases could be induced as a side effect of superantigen exposure (52, 56, 57) .
Finally, the results presented in this study question frequently used animal models. An interesting and largely unexplained finding in murine transplantation systems is the fact that in a fully mismatched setting (H2 d 3 H2 b /C57BL/6) DBA/2 (H2 d ) organs and cells are usually less immunogeneic than those from BALB/c (H2 d ). The minor mismatches between the two strains (BALB/c vs DBA/2) are an unlikely explanation for this finding. The most striking finding is that DBA/2 kidney transplants show a markedly prolonged, sometimes indefinite, survival in C57BL/6 recipients, whereas BALB/c kidneys are usually rejected within 10 days. The survival of the allografts in that system directly correlates with the frequency of FoxP3 ϩ recipient T cells within the transplanted kidney (58) . Endogenous Ags and/or superantigens cannot only be transferred between individual animals during transplantation but also during pregnancy. It is therefore conceivable that noninherited maternal Ags (NIMA) might shape the immune repertoire of the fetus. Two recent reports (59, 60) looked at the possible regulatory effect NIMA using the following breeding pair: B6D2F 1 Ǩ (C57BL/6 ϫ DBA/2, H2 bxd ) ϫ C57BL/6Z (H2 b ), which led to either C57BL/6 or C57BL/6 ϫ DBA/2 offspring. In their experiments, the authors showed that the C57BL/6 (H2 b ) offspring developed NIMA-specific (H2 d ) CD4 ϩ CD25 ϩ regulatory T cells, which could dominantly suppress effector T cells in solid organ and bone marrow transplantation when transplanting these animals with B6D2F1 (H2 bxd ) tissue. Remarkably, both studies stated that the observed tolerance could only be induced in the shown strain combinations without providing an explanation for this finding. In fact, in both studies, the NIMA were copresented with endogenous superantigens because they used B6D2F 1 (C57BL/6 ϫ DBA/2) mothers, which are virtually devoid of any V␤6 ϩ T cells (our unpublished data). Taken together, with studies from Ribot et al. (61) , which showed the potential of Mls-1 a to specifically induce regulatory T cells in an MHC-mismatched model, it is tempting to speculate that the above findings are rather the result of a high frequency of superantigen-activated regulatory T cells than conventional (MHC-peptide) reactive regulatory T cells. Future studies will be needed to test this hypothesis.
In considering the therapeutic implications of our findings, two different approaches have been suggested in exploiting the function of regulatory T cells to induce tolerance in autoimmunity, graft-vs-host disease, and transplantation. The first is to expand ex vivo large numbers of polyclonal or Ag-specific regulatory T cells and then transfer them in vivo; the second is to induce/expand regulatory T cells directly in vivo. For the latter approach, the results presented in this study suggest that the advantage of providing a "head start" to regulatory T cells is crucial to achieve effective inhibition of both innate and adaptive immune responses.
